iLoF - Intelligent Lab on Fiber

Based in the UK, Intelligent Lab on Fiber (iLoF) builds digital, cloud-based libraries of biomarkers and biological profiles by leveraging AI and photonics. The AI platform gathers large sets of biological data in the form of optical signals—collected via blood samples including frozen samples—that are converted into phenotypic signatures. It creates digital twins of biological profiles and disease subtypes and screens through its database to identify any matches, potentially expediting the drug discovery and development of novel personalized medicines by pharma and biotech companies. iLoF’s platform is reportedly capable of delivering results in less than 10 seconds and also enables the samples to be used multiple times. With initial focus on Alzheimer’s disease, the company intends to expand its potential to other diseases. iLoF’s laboratory is based in Poland. 

Funding and financials

In July 2022, iLoF raised EUR 4 million (USD 4.1 million) in a seed funding round led by Faber, with participation from Microsoft's venture fund, M12. It also secured a USD 0.1 million grant from the European Regional Development Fund (ERDF), bringing the company’s total funds raised to date to USD 8 million. The funds were earmarked for accelerating the company’s global partnerships and advancing its drug development platform.